Age-Related Macular Degeneration
Positive preliminary clinical results presented on EVIZON for treatment of AMD
Published in Drug Week, November 25th, 2005
EVIZON with concomitant PDT was well-tolerated in all subjects with no drug-related serious adverse events reported to date. The most common adverse events involved infusion site reactions. These events were generally mild and were distributed evenly across the EVIZON plus PDT treatment groups. Preliminary data were presented for 40 mg or 20 mg of EVIZON with concomitant PDT compared with...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2005-11-25)
More Articles from Drug Week
- Drug Development
ALTU-135 well tolerated in cystic fibrosis patients with pancreatic insufficiency - Obesity Therapy
Phase IIa trial data indicate statistically significant weight loss in obese patients taking APD356 - Pharmaceutical Research
Antibiotic daunomycin binds to human serum albumin at nonclassical drug binding site - Rhinitis
PreHistin significantly reduces allergy symptoms in 714-patient phase III clinical trial - Adverse Drug Reaction
Patients develop acute liver failure after receiving amoxicillin/clavulanate - Allergy & Immunology
Donor HLA alleles may control hepatitis C virus spread to liver grafts - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
